An individual participant data meta-analysis clarifies which elements of collaborative care most effectively reduce depressive symptoms in primary care, informing implementation strategies for clinicians...
A randomized clinical trial in Pakistan evaluated whether structured, measurement-based care could accelerate antidepressant response and remission in adults with major depressive disorder compared with...
The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.
In two pragmatic randomized trials conducted in the Capital Region of Denmark, investigators compared collaborative care with consultation liaison in general practice to assess whether greater involvement...
Recent research found that soft drink consumption may be linked to major depressive disorder diagnosis and increased depressive symptom severity, with significant associations observed only among women.
...
In an FDA panel held on July 21, 2025, experts discussed the nuances of risk-benefit counseling and stronger warnings for selective serotonin reuptake inhibitors (SSRIs) to ensure informed consent among...
Amid rising rates of adolescent mental health issues, especially following the COVID-19 pandemic, primary care providers are uniquely positioned to identify and treat conditions like depression and anxiety...
